News Juno halts CAR-T trial again after 2 more deaths Doubts over Juno CAR-T therapy after two more trial deaths.
News Kite outlines vision for next gen cancer killing cells Backed by Amgen, Kite outlines bold plan for developing CAR-T and TCR cells.
News Three's a crowd as Tecentriq approved in lung cancer Cancer immunotherapy approved in second line.
Partner Content Partner Content On Demand: The Top 5 Challenges in Immuno-Oncology Trials In the battle against cancer, immunotherapy is proving to be one of the most promising avenues of research.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
